Right, so welcome everybody. It sounds like we have fellows from all years, and we're going to talk about how to critically evaluate clinical trials.

Thank you so much for coming. I'm Vinay Prasad. I'm a professor of epidemiology and biostatistics here.

I'm also in the Department of Medicine. I'm a hemank attending here at SFGH and the VA. So if any of you pass through and do that consult service,

we might overlap. I also do clinic at the general and soon to be at the VA too. So I wanted to

start by getting us to reflect a little bit about what shapes our interpretation of cancer medicine.

And I think for many of us, our interpretation of cancer medicine, if we're

perfectly honest, it's not mostly shaped by peer review articles. In fact, a lot of what we

learn in oncology in fellowship and a lot of what we learn year after year is from other sources.

For instance, the NCCN guidelines. I mean, how often are you in clinic and you have the NCCN guidelines open?

And then all of the people that email you every day, Onk Live, Cancer Today, whatever that VJ Hemank is, they email you and you might not read all of it, but you might read the headline.

Very rarely they'll post a video, and I know that not many of you are reading it,

maybe 20, 30 people are. Asco Post and podcasts, there are a number of excellent oncology

podcasts. I make one plenary session, and there are a bunch of other ones I listen to, and there's

a bunch of other ones I don't listen to, but I know they're out there. Journals, I like to look at journal articles, and I think you do too, here and there.

Conferences.

And then the industry, the representatives, their advertisements.

Finally, our colleagues, how many things do we learn in oncology because somebody tells you,

hey, you hear about that new cartese, you hear about that new drug, hear about that new, etc.

So much of it is just from word of mouth.

And then finally, ourselves.

And this is really a talk that's about that last category, ourselves.

Because ultimately, I think going forward, we have so much information flooding us.

...